Rating Change
Barclays analysts initiated coverage on Insulet Corporation (NASDAQ:PODD) with a rating of Equal-Weight on October 07, 2026.
Barclays analysts initiated coverage on Insulet Corporation (NASDAQ:PODD) with a rating of Equal-Weight on October 07, 2026.

At publication ·
Insulet Corporation (NASDAQ:PODD) · new coverage
At a glance
Barclays analysts initiated coverage on Insulet Corporation (NASDAQ:PODD) with a rating of Equal-Weight on October 07, 2026.
Insulet Corporation operates in the Healthcare sector. The stock currently trades at $134.36 with a market capitalization of $20.7B. The stock has declined 53.8% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Insulet Corporation.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 4 Buy, 6 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 07, 2026 | Barclays | Equal-Weight | N/A |
| Aug 06, 2026 | Leerink Partners | Market Perform | N/A |
| Aug 06, 2026 | Benchmark | Buy | N/A |
| Aug 06, 2026 | Bernstein | Outperform | N/A |
| Aug 06, 2026 | RBC Capital | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View PODD Stock Page
A rating of Equal-Weight from Barclays reflects the analyst's outlook on Insulet Corporation (NASDAQ:PODD). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PODD forecast page.
Current market data
NASDAQ · PODD
Keep reading